Recently, Zhejiang Chengyi Pharmaceutical Co., Ltd. announced that its key product, Torasemide Tablets, has received a Drug Registration Certificate from China’s National Medical Products Administration (NMPA). This approval marks a significant step forward for Chengyi in the cardiovascular and diuretic therapeutic areas and enhances the company’s product portfolio and market competitiveness.Torasemide is a potent and highly selective loop diuretic primarily used to treat edema caused by conditions such as congestive heart failure, liver cirrhosis, or nephrotic syndrome, as well as essential hypertension. Compared with conventional diuretics, torasemide offers faster onset, longer duration of action, and a lower risk of electrolyte imbalances, making it widely used and clinically effective.The approved Torasemide Tablets are a generic version that has passed China’s bioequivalence and quality consistency evaluation, confirming therapeutic equivalence to the originator drug. This not only helps reduce treatment costs for patients but also supports the broader national initiative to replace imported drugs with high-quality domestic generics.Chengyi Pharmaceutical stated that it will accelerate the commercial rollout of this product and continue to increase R&D investment to expand its pipeline in cardiovascular and chronic disease treatments, further solidifying its position as a specialized player in the pharmaceutical industry.
近日，浙江诚意药业股份有限公司宣布其核心产品托拉塞米片获得国家药品监督管理局（NMPA）颁发的药品注册证书。该证书的获批标志着诚意药业在心血管及利尿药物领域迈出关键一步，也为其产品线拓展和市场竞争力提升注入新动力。托拉塞米是一种高效、选择性强的袢利尿剂，主要用于治疗因充血性心力衰竭、肝硬化或肾病综合征等引起的水肿，以及原发性高血压。与传统利尿剂相比，托拉塞米具有起效快、作用时间长、电解质紊乱风险较低等优势，临床应用广泛且疗效确切。此次获批的托拉塞米片为仿制药，通过了一致性评价，意味着其在质量和疗效上与原研药相当。这不仅有助于降低患者用药成本，也将推动国产高质量仿制药替代进口产品的进程。诚意药业表示，公司将依托此次注册获批，加快该产品的商业化布局，并持续加大研发投入，丰富心脑血管及慢性病治疗领域的产品管线，进一步巩固其在医药行业的专业地位。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/783.html